<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3389/fcell.2020.00064</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>CD151 in Respiratory Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Amanda H.</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/753310/overview"/></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Thai</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref></contrib></contrib-group><aff><institution>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Randall Glenn Worth, The University of Toledo, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Kazuyuki Tsujino, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan; Reinoud Gosens, University of Groningen, Netherlands</p></fn><corresp id="c001">*Correspondence: Thai Tran, <email>tran_thai@nuhs.edu.sg</email>; <email>phstt@nus.edu.sg</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>8</volume><elocation-id>64</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Wong and Tran.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wong and Tran</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The tetraspanin, Cluster of Differentiation 151 (CD151), is ubiquitously expressed in adult tissue, especially in the lungs where it has been implicated in lung cancer, asthma, influenza, and idiopathic pulmonary fibrosis (IPF). CD151 interacts with laminin-binding integrins and growth factor receptors, and is reported in cancer-promoting processes such as tumor initiation, metastasis, and angiogenesis. In asthma, CD151 was shown to promote airways hyperresponsiveness through calcium signaling whereas in influenza, CD151 was shown to be a novel host factor for nuclear viral export signaling. Furthermore, CD151 was shown to be associated with increased disease severity and poorer survival outcome in asthma and lung cancer, respectively. In this review, we provide an update on the current understanding of CD151 with regards to its contribution to lung pathophysiology. We also summarize factors that have been shown to regulate CD151 expression and identify key areas that need to be taken into consideration for its utility as a screening or prognostic tool in disease management and/or as a therapeutic target for the treatment of lung diseases.</p></abstract><kwd-group><kwd>CD151</kwd><kwd>lung cancer</kwd><kwd>asthma</kwd><kwd>influenza</kwd><kwd>idiopathic pulmonary fibrosis</kwd><kwd>biomarker</kwd><kwd>targeted therapy</kwd><kwd>tetraspanin</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Ministry of Education - Singapore<named-content content-type="fundref-id">10.13039/501100001459</named-content></funding-source></award-group><award-group><funding-source id="cn002">National University Health System<named-content content-type="fundref-id">10.13039/501100011744</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="93"/><page-count count="9"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Respiratory diseases account for significant illness and premature mortality around the world. The global impact of respiratory diseases is difficult to quantify due to discrepancies or insufficient data across regions, however, the socioeconomic burden of these conditions cannot be ignored. More than 9.5 million deaths globally were attributed to respiratory diseases &#x02013; the most common of which were asthma, lower respiratory infections, chronic obstructive pulmonary disease, and lung cancer &#x02013; and the total cost of respiratory diseases in the European Union alone was estimated to total over &#x020ac;380 billion annually (<xref rid="B21" ref-type="bibr">Gibson et al., 2013</xref>; <xref rid="B15" ref-type="bibr">Ferkol and Schraufnagel, 2014</xref>). Whilst risk factors such as air pollution, tobacco smoke exposure, occupational agents, and genetics (<xref rid="B21" ref-type="bibr">Gibson et al., 2013</xref>) have been identified, respiratory diseases are not curable in some cases and current treatment options are suboptimal for the majority of patients with chronic respiratory diseases. Hence, the development of novel therapies is required to alter the progression of disease severity and/or prevent disease onset.</p><p>In this review, we provide an update on the current understanding of CD151 with regards to its contribution to lung physiology and pathophysiology (<xref ref-type="fig" rid="F1">Figure 1</xref>). We also summarize factors that have been shown to regulate CD151 expression and identify key areas that need to be taken into consideration for its utility in disease management as a screening or prognostic tool and as targeted or adjuvant therapy.</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Contribution of CD151to respiratory diseases. ASM, airway smooth muscle; IPF, idiopathic pulmonary fibrosis; MMP7, matrix metalloproteinase-7; NSCLC, non-small cell lung cancer.</p></caption><graphic xlink:href="fcell-08-00064-g001"/></fig></sec><sec id="S2"><title>CD151</title><p>Cluster of Differentiation 151 was first identified as a platelet surface glycoprotein, gp27, where it was found to induce platelet aggregation and mediator release (<xref rid="B3" ref-type="bibr">Ashman et al., 1991</xref>). Following successful cloning of the cDNA encoding gp27, it was shown to belong to the transmembrane 4 superfamily, tetraspans, and renamed Platelet-Endothelial cell Tetra-span Antigen-3 (PETA-3) (<xref rid="B17" ref-type="bibr">Fitter et al., 1995</xref>). The following year, another team independently identified the same protein but named it protein SFA-1 as it was induced by a T-cell leukemia cell line, SF-HT. The protein was subsequently reassigned as Cluster of Differentiation 151 (CD151) (<xref rid="B2" ref-type="bibr">Ashman, 2002</xref>). Whilst early reports identified CD151 as a surface protein, CD151 is also expressed intracellularly (<xref rid="B29" ref-type="bibr">Hwang et al., 2019</xref>), including cytoplasmic vesicles, endothelial cell junctions and perinuclear regions (<xref rid="B48" ref-type="bibr">Liu et al., 2007</xref>; <xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>).</p><p>Like other tetraspanin family members, CD151 forms lateral associations with multiple partner proteins within the tetraspanin-enriched microdomain (TEM). The most prominent partners of CD151 are laminin-binding integrins (<xref rid="B48" ref-type="bibr">Liu et al., 2007</xref>), whilst adhesion molecules, growth factor receptors, metalloproteinases, and intracellular signaling molecules have also been shown to be associated with CD151 or be localized within TEMs (<xref rid="B23" ref-type="bibr">Hemler, 2003</xref>; <xref rid="B75" ref-type="bibr">Stipp et al., 2003</xref>). In addition to membrane clustering and organization, they have been shown to modulate, stabilize or prevent the activities of their associate molecules to influence cell activation, proliferation, migration, adhesion, and signaling.</p><p>Cluster of Differentiation 151 is widely expressed in multiple cell types of normal human tissue (<xref rid="B74" ref-type="bibr">Sincock et al., 1997</xref>). Immunohistochemical staining showed that CD151 was found to be strongly positive in the lungs, specifically in airway smooth muscle (<xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>), epithelial layers, endothelial cells and blood vessels (<xref rid="B74" ref-type="bibr">Sincock et al., 1997</xref>). Given its abundance in lung tissue, the role of CD151 in normal and pathological processes in airways is especially relevant.</p><sec id="S2.SS1"><title>CD151 in Development and Maintenance of Lung Structure</title><p>The role of CD151 in normal lung physiology is not fully explored but inferences about its critical role can be made from clinical cases of CD151 gene mutation and from studies in mice where CD151 is deleted. With regards to clinical cases of CD151 gene mutation, there have been six reported case studies of patients with CD151 gene mutations resulting in truncated or altered forms of the protein. Nephropathy was reported in four of the cases as well as epidermolysis bullosa and sensorineural deafness in two cases (<xref rid="B32" ref-type="bibr">Karamatic Crew et al., 2004</xref>; <xref rid="B83" ref-type="bibr">Vahidnezhad et al., 2018</xref>). The remaining two cases, with a single base substitution, exhibited no significant clinical outcomes (<xref rid="B33" ref-type="bibr">Karamatic Crew et al., 2008</xref>). Differences in lung function or morphology were not reported in these patients &#x02013; whether genetic mutations of CD151 had no effect on lung physiology and therefore it was not reported, or whether the investigators did not look at other organ phenotypes is not known. In CD151-null mice, several studies have recapitulated the significant role of CD151 in kidney, skin and inner ear function (<xref rid="B85" ref-type="bibr">Wright et al., 2004</xref>; <xref rid="B67" ref-type="bibr">Sachs et al., 2006</xref>). Interestingly, <xref rid="B82" ref-type="bibr">Tsujino et al. (2012)</xref> reported that CD151 is essential for the normal function of alveolar epithelial cells (APCs) as the deletion of CD151 in APCs resulted in the loss of epithelial integrity (loss of epithelial adhesion to the basement membrane). In addition, there were increases in collagen deposition, collagen-1 expression and hydroxyproline content in the lungs of the CD151-null mice and lung compliance was also reduced in these mice as compared to wildtype control mice. The authors concluded that CD151 functions to protect against pulmonary fibrosis by maintaining epithelial integrity.</p><p>Besides these reports, findings from other groups may be informative in understanding the physiological role of CD151. Treatment with anti-CD151 antibody resulted in the loss of epithelial integrity in skin epithelial cells (<xref rid="B71" ref-type="bibr">Shigeta et al., 2003</xref>) whilst CD151 knockdown was shown to disrupt integrin-mediated adhesion to the basement membrane (<xref rid="B86" ref-type="bibr">Yamada et al., 2008</xref>). Both these processes are crucial for the development and maintenance of lung structure. Given the strong interaction between CD151 and its laminin-binding partners, defects in bronchi morphogenesis and lung deficiencies observed with the deletion of integrin &#x003b1;3&#x003b2;1 (<xref rid="B41" ref-type="bibr">Kreidberg et al., 1996</xref>) and laminin-&#x003b1;5 (<xref rid="B56" ref-type="bibr">Nguyen et al., 2002</xref>), respectively, cannot be overlooked and further studies have to be conducted to conclusively determine whether the physiological conditions observed are a direct consequence of CD151 dysregulation or a secondary effect of CD151 due to disruption of its laminin-binding partners.</p></sec><sec id="S2.SS2"><title>Tumor Promoter in Lung Cancer</title><p>Lung cancer has a high degree of molecular heterogeneity thus giving rise to diverse pathological features. Cases are classified according to respective histological characteristics leading to the distinction between small and non-small cell lung cancer (NSCLC) (<xref rid="B24" ref-type="bibr">Herbst et al., 2008</xref>). The onslaught of molecular targets has driven a shift in therapeutic management from conventional cytotoxic drugs to targeted molecular targeted therapy (<xref rid="B26" ref-type="bibr">Hirsch et al., 2017</xref>; <xref rid="B25" ref-type="bibr">Herbst et al., 2018</xref>). The pathogenesis of lung cancer and its management has been covered extensively by others in the preceding reviews. CD151 was the first tetraspanin to be identified as a tumor promoter (<xref rid="B79" ref-type="bibr">Testa et al., 1999</xref>). The authors found that the monoclonal antibody raised against CD151 was capable of inhibiting both spontaneous and experimental metastasis in the chick embryo chorioallantoic membrane model. Since then, CD151 overexpression has been implicated as a negative prognostic indicator in numerous solid malignancies (<xref rid="B1" ref-type="bibr">Ang et al., 2004</xref>; <xref rid="B10" ref-type="bibr">Chien et al., 2008</xref>; <xref rid="B35" ref-type="bibr">Ke et al., 2009</xref>; <xref rid="B76" ref-type="bibr">Suzuki et al., 2011</xref>; <xref rid="B43" ref-type="bibr">Kwon et al., 2012</xref>; <xref rid="B45" ref-type="bibr">Lee et al., 2012</xref>; <xref rid="B31" ref-type="bibr">Kang et al., 2013</xref>; <xref rid="B64" ref-type="bibr">Romanska et al., 2013</xref>; <xref rid="B16" ref-type="bibr">Fisher et al., 2016</xref>; <xref rid="B52" ref-type="bibr">Medrano et al., 2017</xref>).</p><p>In NSCLC, several studies have shown that CD151 overexpression, measured by gene expression and immunohistochemical analysis, is associated with poorer prognosis in terms of survival rate (<xref rid="B81" ref-type="bibr">Tokuhara et al., 2001</xref>) or overall and disease-free survival (<xref rid="B44" ref-type="bibr">Kwon et al., 2013</xref>). Exosome protein profiling comparing a cohort of lung cancer patients with non-cancer patients revealed that CD151 was one of the markers found to be upregulated in lung cancer (<xref rid="B69" ref-type="bibr">Sandfeld-Paulsen et al., 2016</xref>). This study showed that whilst CD151 expression was detected on structural or immune cells, these cells also secreted CD151-containing exosomes in circulation to act as components for crosstalk between cancer initiating cells and their environment (<xref rid="B91" ref-type="bibr">Yue et al., 2015</xref>). This highlights their key role in cancer and as a mediator of cell-cell communication.</p><p>Use of gene deletion technology and/or use of monoclonal antibodies directed at CD151 have been employed to explore the functional significance of CD151. In lung cancer cells, CD151 knockdown resulted in impairment of several cancer-promoting processes including cell survival, migration, invasion, and matrix adhesion. These changes were mainly due to CD151 interaction with partner or associated proteins such as integrin &#x003b1;3&#x003b2;1 (<xref rid="B86" ref-type="bibr">Yamada et al., 2008</xref>), matrix metalloproteinase-9, vascular endothelial growth factor (<xref rid="B46" ref-type="bibr">Li et al., 2015</xref>) and hepatocyte growth factor (<xref rid="B18" ref-type="bibr">Franco et al., 2010</xref>), and subsequently downstream signaling of these proteins. In spontaneous lung metastasis models, CD151-null mice exhibited a marked delay in tumor initiation and a decrease in number of metastastic lesions (<xref rid="B13" ref-type="bibr">Deng et al., 2012</xref>; <xref rid="B11" ref-type="bibr">Copeland et al., 2013</xref>). Similarly, when tumor cells were injected at a separate primary site, CD151-null mice also showed reduced lung metastasis and tumor cell residence (<xref rid="B77" ref-type="bibr">Takeda et al., 2007</xref>, <xref rid="B78" ref-type="bibr">2011</xref>; <xref rid="B68" ref-type="bibr">Sadej et al., 2010</xref>).</p></sec><sec id="S2.SS3"><title>Hyperresponsiveness Mediator in Asthma</title><p>Asthma is a chronic airway disease characterized by three main features, airways hyperresponsiveness, airway wall remodeling and airway inflammation (<xref rid="B5" ref-type="bibr">Barnes, 1996</xref>; <xref rid="B42" ref-type="bibr">Kudo et al., 2013</xref>). Current asthma treatment is mainly focused on long-term clinical control of asthma and rapid-acting symptom relief. However, these drugs are suboptimal in controlling disease, for example in the case of the widely prescribed inhaled corticosteroids which are limited in its clinical efficacy due to varying responsiveness in the population and increased risk of adverse effects when administered at higher doses (<xref rid="B6" ref-type="bibr">Bateman et al., 2008</xref>; <xref rid="B62" ref-type="bibr">Reddel et al., 2015</xref>). Therefore, a better understanding of underlying mechanisms of disease and therapeutic targeting of these mechanisms may contribute greatly to improved asthma management.</p><p>Expression of CD51 is clinically relevant to asthma as immunohistochemical analysis of human bronchial biopsy specimens for CD151 expression in airway smooth muscle bundles were highest in mild or moderate asthma subjects compared with non-asthmatic subjects (<xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>). In the same study, CD151 was implicated to play a role in airways hyperresponsiveness &#x02013; loss- and gain-of-function studies showed that CD151 enhances G protein-coupled receptor (GPCR)-induced calcium and protein kinase C signaling, which are key signaling pathways implicated in airway smooth muscle cell contraction. In support, CD151-null mice did not exhibit increased airway reactivity to contractile agonists and were shown to have increased lung compliance compared to the wild-type group (<xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>). This study is significant as it provides a better understanding of the mechanism for airways hyperresponsiveness which may help in the design of more efficacious and emerging therapies for asthma. What remains to be determined is whether high CD151 expression is a result of asthma or whether elevated expression of CD151 results in asthma. Furthermore, the impact of CD151 on the remaining key features of asthma, airway wall remodeling, and airway inflammation, is yet to be established.</p></sec><sec id="S2.SS4"><title>Host Factor in Influenza Viral Export</title><p>An estimated 5% of adults develop influenza symptoms annually with severe cases leading to conditions such as bronchitis and pneumonia. These seasonal epidemics are largely due to influenza viruses A and B. Influenza viruses are segmented, negative-sense RNA viruses within a lipid envelope containing the surface glycoproteins hemagglutinin and neuraminidase &#x02013; involved in viral entry and progeny release, respectively (<xref rid="B57" ref-type="bibr">Nicholson et al., 2003</xref>; <xref rid="B72" ref-type="bibr">Shim et al., 2017</xref>). Tetraspanins are reported to play critical roles in multiple virus life cycle processes such as virus entry, endocytosis, intracellular trafficking, assembly and budding (<xref rid="B84" ref-type="bibr">van Spriel and Figdor, 2010</xref>). CD151 was previously implicated in several viral infections including papillomavirus, cytomegalovirus and human immunodeficiency virus (<xref rid="B80" ref-type="bibr">Thali, 2011</xref>; <xref rid="B70" ref-type="bibr">Scheffer et al., 2014</xref>; <xref rid="B27" ref-type="bibr">Hochdorfer et al., 2016</xref>). CD151 plays a critical role in influenza A virus signaling (IAV) (<xref rid="B60" ref-type="bibr">Qiao et al., 2018</xref>). The knockdown of CD151 expression in patient-derived nasal epithelial cells resulted in a significant reduction in IAV progeny viral load. In addition, CD151-null mice were more resistant and tolerant to IAV infection with higher survival rates as compared to the wild-type infected mice. With regards to respiratory infection, the anti-viral responses were attributed to CD151 mediating the export of progeny viruses through its binding to newly synthesized viral proteins (NP, M1, and NEP) and host nuclear export protein (CRM1). The novel action of CD151 on viral nuclear export signaling associated with H3N2 and H1N1 infection (<xref rid="B60" ref-type="bibr">Qiao et al., 2018</xref>) highlights the potential of CD151 to be developed as a novel therapy to treat influenza and other viral infections. Targeting CD151 is especially beneficial given that it targets a host mechanism thus making it less susceptible to constant changes in viral strains &#x02013; due to antigenic shift and antigenic drift &#x02013; that render current antiviral drugs or vaccines ineffective after each season.</p></sec><sec id="S2.SS5"><title>Protective or Progressive Role in Idiopathic Pulmonary Fibrosis</title><p>Idiopathic pulmonary fibrosis (IPF) is a form of interstitial pneumonia that features the chronic and progressive scarring of the lung. Initially regarded as an inflammatory disease, recent reports have highlighted the importance of AECs activation in causing repetitive injury in IPF (<xref rid="B37" ref-type="bibr">King et al., 2011</xref>; <xref rid="B63" ref-type="bibr">Richeldi et al., 2017</xref>). This triggers the recruitment of immune cells and fibroblasts in the lung microenvironment and initiates the remodeling of the extracellular matrix and lung regeneration (<xref rid="B49" ref-type="bibr">Martinez et al., 2017</xref>; <xref rid="B54" ref-type="bibr">Mora et al., 2017</xref>).</p><p>Interestingly, CD151-null mice spontaneously developed pulmonary fibrosis features observed at 30 weeks and exhibited accelerated bleomycin-induced lung injury in the pulmonary fibrosis model, suggesting a protective role of CD151 in IPF. This was attributed to the critical function of CD151 in maintaining AECs integrity, and that CD151 deletion attenuates AECs adhesion to the basement membrane, upregulates transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1) signaling in AECs and promotes epithelial-mesenchymal transition changes. In support of this, CD151-negative AECs were focally observed in lung biopsies from IPF patients. However, it is unclear if the IPF phenotype observed in CD151-null mice is strain-specific as differences in renal function in tumor formation (<xref rid="B47" ref-type="bibr">Li et al., 2013</xref>) has been observed between FVB/N background [generated using 129SvEv ES cells (<xref rid="B77" ref-type="bibr">Takeda et al., 2007</xref>; <xref rid="B82" ref-type="bibr">Tsujino et al., 2012</xref>)] versus C57BL/6 mice [generated from 129/Ola and C57BL/6 ES cells (<xref rid="B85" ref-type="bibr">Wright et al., 2004</xref>)]. Importantly, whether similar phenotypes are observed in patients with CD151 mutations remains to be explored.</p><p>In contrast to the report above describing the protective role of CD151 in IPF, <xref rid="B19" ref-type="bibr">Fujishima et al. (2010)</xref> proposed that interactions between CD151 and MMP-7 (for which expression is elevated in IPF patients) could contribute to worsening of IPF condition. They show that CD151 facilitates MMP-7 activation by acting as a docking molecule (<xref rid="B73" ref-type="bibr">Shiomi et al., 2005</xref>) and was colocalized with pro-MMP-7 in sections of lung tissue from IPF patients. However, CD151 levels in these IPF patient samples were not directly measured in this study (<xref rid="B19" ref-type="bibr">Fujishima et al., 2010</xref>). In support, CD151 has been implicated in other fibrotic processes, such as liver fibrosis and skin wound healing (<xref rid="B51" ref-type="bibr">Mazzocca et al., 2002</xref>; <xref rid="B20" ref-type="bibr">Geary et al., 2008</xref>). Therefore, more studies are warranted to clearly define the role of CD151 in fibrosis in general and IPF more specifically.</p></sec></sec><sec id="S3"><title>Regulation of CD151 Expression</title><sec id="S3.SS1"><title>CD151 Expression Modulators</title><p>Given the importance of CD151 in respiratory diseases, it is interesting to note that little is known about regulators of CD151 expression changes. To date, there are only two studies that report that the expression of CD151 mRNA and protein abundance are modulated by therapies &#x02013; anti-epileptic drugs and anti-cancer drugs, respectively (<xref rid="B28" ref-type="bibr">Hua et al., 2001</xref>; <xref rid="B29" ref-type="bibr">Hwang et al., 2019</xref>). The study conducted by <xref rid="B28" ref-type="bibr">Hua et al. (2001)</xref> showed that chronic administration of the anti-epileptic drugs, carbamazepine or valproate, significantly decreased CD151 transcript levels in rat frontal cortex following chronic (five-week) treatment. The functional significance of this reduction was not explored in this study and there have been no followup studies to date by this group or others. In contrast to that, a recent study by <xref rid="B29" ref-type="bibr">Hwang et al. (2019)</xref> showed that several anti-cancer drugs (gefitinib, lapatinib, cisplatin, oxaliplatin, camptothecin, and 5-fluorouracil) induced CD151 protein levels in A431 skin epidermoid carcinoma cells. They further showed that gefitinib upregulated CD151 protein levels in MDA-MB-231 breast and A549 lung carcinoma cell lines, respectively. In this study, the group showed that anti-cancer drug resistance may in part be attributed to CD151 upregulation, for which CD151 knockdown sensitized the cells to drug treatment. It remains to be seen whether these effects could be translated to <italic>in vivo</italic> conditions.</p><p>Besides drug-induced regulation, hypoxic conditions were shown to regulate CD151 expression and subsequently cell adhesion and metastasis. Hypoxia is the condition of oxygen deficiency and is a major driver of cancer-promoting processes such as angiogenesis and migration. Hypoxia is mainly mediated through hypoxia-inducible factors (HIF) (<xref rid="B36" ref-type="bibr">Ke and Costa, 2006</xref>). In this study, the expression of CD151 was downregulated under hypoxic conditions via the HIF-1&#x003b1;-dependent pathway in colorectal cells. HIF-1&#x003b1; dependency was further confirmed when CD151 levels were inhibited by HIF-1&#x003b1; induction through treatment with desferrioxamine (hypoxia-mimetic agent) or overexpression with plasmid vectors (<xref rid="B10" ref-type="bibr">Chien et al., 2008</xref>). It remains to be observed whether the same hypoxic conditions can reduce CD151 in a lung cancer setting.</p></sec><sec id="S3.SS2"><title>Mechanisms Underlying CD151 Regulation</title><p>Whilst CD151 expression modulation plays a critical role in determining disease progression, whether in promoting pathophysiology of lung cancer, asthma, and influenza or in potentially protecting against IPF, there is a distinct gap in the literature pertaining to the mechanisms underlying these changes. In the study reporting CD151 mRNA downregulation after treatment with anti-epileptic drugs, valproate and carbamazepine (<xref rid="B28" ref-type="bibr">Hua et al., 2001</xref>), there were no experiments conducted to explain gene expression changes or whether downstream protein expression was affected. Whereas in the anti-cancer drug-induced CD151 study (<xref rid="B29" ref-type="bibr">Hwang et al., 2019</xref>), the authors ruled out integrin dependence and proposed that CD151 upregulation may be due to diminished protein degradation. However, there are no reports to date to corroborate this proposal.</p><p>Interestingly, the mechanism underlying hypoxia-mediated downregulation of CD151 was determined to be at the transcriptional level (<xref rid="B10" ref-type="bibr">Chien et al., 2008</xref>). In addition to the decrease in CD151 protein expression under hypoxic conditions, CD151 mRNA levels were also reduced significantly in hypoxic compared to normoxic conditions. This reduction in mRNA levels was confirmed with desferrioxamine treatment. The group went on to identify a putative hypoxia-response element (HRE) in the human CD151 promoter region and intron II, suggesting a direct action on CD151 regulation by hypoxia exposure.</p><p>In addition to transcriptional regulation of CD151 expression, another area that may be explored is post-translational modifications. Several reports have previously identified six intracellular C- terminal cysteine sites on CD151 that are palmitoylated, that is, C11, C15, C79, C80, C242, and C243 (<xref rid="B7" ref-type="bibr">Berditchevski et al., 2002</xref>; <xref rid="B88" ref-type="bibr">Yang et al., 2002</xref>). Besides palmitoylation, CD151 may also undergo glycosylation at the asparagine residue, N159 (<xref rid="B4" ref-type="bibr">Baldwin et al., 2008</xref>). However, palmitoylation and glycosylation modifications have not exhibited differences in expression levels or staining pattern (<xref rid="B4" ref-type="bibr">Baldwin et al., 2008</xref>; <xref rid="B92" ref-type="bibr">Zevian et al., 2011</xref>). Also, the effect of drug treatment on these post-translational modifications has not been elucidated. Besides palmitoylation and glycosylation of CD151, the post-translational modification of ubiquitination should also be explored as it may be informative with regards to CD151 protein stability.</p></sec></sec><sec id="S4"><title>Key Considerations for CD151 in the Management of Lung Diseases</title><sec id="S4.SS1"><title>CD151 as a Prognostic and Diagnostic Tool</title><p>The prognostic value of CD151 was previously emphasized in low-grade prostate cancer, in which CD151 expression could predict the clinical outcome of patients more accurately than the traditional histological grading method (<xref rid="B1" ref-type="bibr">Ang et al., 2004</xref>). Given the strong association between CD151 and lung cancer (<xref rid="B81" ref-type="bibr">Tokuhara et al., 2001</xref>; <xref rid="B44" ref-type="bibr">Kwon et al., 2013</xref>), especially adenocarcinoma which is the most common NSCLC subtype, CD151 expression has proven to be especially informative on patient prognosis. Furthermore, the prognostic utility of CD151 expression may be extended to other diseases such as asthma, in which the expression of CD151 was associated with disease severity (<xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>).</p><p>Besides immunohistochemical analysis, an emerging technology in determining protein expression is exosome protein profiling. Tetraspanins, including CD151, are shown to be highly enriched in exosomes (<xref rid="B53" ref-type="bibr">Merino et al., 2014</xref>) which may be derived from plasma or urine samples (<xref rid="B30" ref-type="bibr">Jakobsen et al., 2015</xref>) making this method far less invasive than traditional biopsy techniques. The potential of CD151 expression detection in exosomes as a screening tool has been explored where a high level of accuracy (72%) in detecting cancer in adenocarcinoma patients was observed (<xref rid="B69" ref-type="bibr">Sandfeld-Paulsen et al., 2016</xref>). Effective screening methods are especially vital in NSCLC for which 60% of patients are only diagnosed at an advanced stage (<xref rid="B61" ref-type="bibr">Reck et al., 2013</xref>). Whilst this method requires further validation, it may be a promising avenue to complement or improve current diagnostic processes.</p></sec><sec id="S4.SS2"><title>Targeted CD151 Therapy</title><p>Given the role of CD151 in a milieu of processes that contribute to lung disease pathophysiology, targeting CD151 in a clinical setting is justifiable. The most commonly reported method of targeting CD151 is with anti-CD151 monoclonal antibodies. Treatment with these antibodies has been shown to impair cellular processes at multiple cancer stages. Tumor growth potential, neoangiogenesis and metastasis following injection with a hepatocellular carcinoma cell line was also inhibited in mice that were treated with mAb 9B, which was shown to specifically disrupt the interaction between CD151 with integrin &#x003b1;6&#x003b2;1 (<xref rid="B34" ref-type="bibr">Ke et al., 2011</xref>). Two other studies recapitulated the anti-metastasis action in chick embryo models using the monoclonal antibodies, mAb 50-6 (<xref rid="B79" ref-type="bibr">Testa et al., 1999</xref>) and mAb 1A5 (<xref rid="B93" ref-type="bibr">Zijlstra et al., 2008</xref>), which were shown to reduce both spontaneous and experimental metastasis. Similarly, the mAb SFA1.2B4 was shown to impair pulmonary metastasis in mice injected with either colon cancer or fibrosarcoma cell lines (<xref rid="B40" ref-type="bibr">Kohno et al., 2002</xref>). Whether or not these monoclonal antibodies disrupt disease progression in respiratory diseases remain to be explored, although its anti-cancer properties for the treatment of lung cancer are promising.</p><p>Besides the use of monoclonal antibodies, CD151 gene deletion has been instrumental in improving markers of disease outcomes in asthma, influenza, and tumor progression. As described above, CD151 knockdown, through siRNA technology, markedly reduced airway smooth muscle contraction whilst airway hyperresponsive processes decreased significantly in allergen-induced CD151-null mice. Following influenza A virus infection, CD151-null mice exhibited better survival and reduced viral titer, which was attributed to the role of CD151 in nuclear export of viral proteins confirmed using CD151 knockdown experiments. In the context of cancer, both experimental lung metastasis and tumor cell residence were reduced in CD151-null mice. Furthermore, pathologic angiogenesis was impaired in these CD151-null mice despite showing no vascular defects under normal developmental conditions. The impact of CD151 was also reported in breast cancer in which mammary tumor initiation, tumor growth, survival, and metastasis were impaired in CD151-null mice (<xref rid="B90" ref-type="bibr">Yang et al., 2008</xref>; <xref rid="B13" ref-type="bibr">Deng et al., 2012</xref>).</p><p>Despite the promising results with monoclonal antibodies and gene deletion, there are several obstacles that restrict the development of these therapeutic strategies. The ubiquitous expression of CD151 in normal human tissue (<xref rid="B74" ref-type="bibr">Sincock et al., 1997</xref>) and its role under physiological conditions (as described above) warrant further studies to determine whether diminishing CD151 expression for therapeutic benefit in the lungs may lead to unwanted, adverse effects to other healthy cells/organs. In this regard, advancements in targeted drug delivery would be extremely beneficial to avoid off-target effects. Developments in the field of nanotechnology and the advent of nanoparticles or nanocarriers in biomedical research provide another avenue for exploiting the importance of CD151 in lung diseases. Several reviews have summarized the clinical significance of nanomedicine in which binding molecules (such as peptides, aptamers, and antibodies) are utilized in cell-specific or tissue-localized delivery of drugs, compounds or genetic material (<xref rid="B58" ref-type="bibr">Poelstra et al., 2013</xref>; <xref rid="B66" ref-type="bibr">Rosenblum et al., 2018</xref>). For instance, using the nanoparticle-based system, <xref rid="B14" ref-type="bibr">Deshmukh et al. (2018)</xref> were able to deliver the small molecule EGFR-specific inhibitor, erlotinib, specifically to myofibroblasts by means of targeting a transmembrane receptor, platelet-derived growth factor receptor-beta, which is uniquely expressed on myofibroblasts in the liver. This specific delivery to hepatic myofibroblasts was more effective and well-tolerated compared to systemic administration of the drug alone (<xref rid="B14" ref-type="bibr">Deshmukh et al., 2018</xref>). No studies to date have reported the use of CD151-specific binding molecules as a targeting mechanism for drug delivery, but its potential could be explored given the importance of CD151 overexpression in various lung diseases and other human malignancies. Delivery of genetic material to inhibit the expression of CD151, such as in the case of short hairpin RNA or guide RNA for CRISPR/Cas9-based genome editing, is another approach that may be investigated. Also, advancements could be made to improve not only uptake but enhanced retention of drugs (<xref rid="B50" ref-type="bibr">Matsumura and Maeda, 1986</xref>; <xref rid="B38" ref-type="bibr">Klibanov et al., 1990</xref>; <xref rid="B9" ref-type="bibr">Blume et al., 1993</xref>; <xref rid="B8" ref-type="bibr">Blanco et al., 2015</xref>), as well as route of drug administration (local delivery via inhalation versus systemic delivery) (<xref rid="B87" ref-type="bibr">Yan et al., 2016</xref>; <xref rid="B12" ref-type="bibr">Cryer and Thorley, 2019</xref>; <xref rid="B55" ref-type="bibr">Mukherjee et al., 2019</xref>). In addition to that, the magnitude of CD151 reduction required in cases of overexpression will also need to be assessed, specifically whether CD151 expression levels can be ablated completely or must be brought back to a baseline expression to ensure physiological functions are not disrupted. Finally, drug-induced upregulation of CD151 must be taken into account given the importance of expression changes in disease progression and severity.</p><p>Cluster of Differentiation 151 may also play an important role as an adjuvant therapy alongside currently available therapeutics. Given the close association of CD151 with oncogenic drivers including growth factors, such as EGFR (<xref rid="B90" ref-type="bibr">Yang et al., 2008</xref>; <xref rid="B13" ref-type="bibr">Deng et al., 2012</xref>), HER2 (<xref rid="B89" ref-type="bibr">Yang et al., 2010</xref>; <xref rid="B13" ref-type="bibr">Deng et al., 2012</xref>; <xref rid="B65" ref-type="bibr">Romanska et al., 2015</xref>), and HGFR (c-Met) (<xref rid="B39" ref-type="bibr">Klosek et al., 2005</xref>; <xref rid="B18" ref-type="bibr">Franco et al., 2010</xref>; <xref rid="B22" ref-type="bibr">Ha et al., 2014</xref>), CD151 was shown to impair growth factor receptor-dependent processes such as tumor onset, cell growth, spreading and motility. CD151 ablation in these studies was sufficient to arrest or impair oncogenic responses. Furthermore, in the case of EGFR and HER2-specific inhibitors, drug sensitivity was restored when CD151 expression was abrogated (<xref rid="B29" ref-type="bibr">Hwang et al., 2019</xref>). Restoration of drug sensitivity with CD151 knockdown was shown to not be restricted to targeted therapy but also observed in chemotherapeutic drugs oxaliplatin, cisplatin, and 5-fluorouracil, via apoptotic induction.</p></sec></sec><sec id="S5"><title>Conclusion</title><p>Cluster of Differentiation 151 is involved in numerous physiological and pathophysiological processes. Therefore, it has been implicated in several diseases, including respiratory diseases such as lung cancer, asthma, influenza and IPF (<xref ref-type="fig" rid="F1">Figure 1</xref>). The majority of studies link CD151 to disease onset, severity or progression. The mechanisms underlying CD151 upregulation or downregulation remain to be fully understood. Nonetheless, the clinical significance of CD151 expression shows that CD151 has great potential to be developed as a diagnostic biomarker which may be helpful for early detection or screening, or as a prognostic biomarker given its relevance in predicting lung cancer or asthma severity. Furthermore, CD151 monoclonal antibodies, gene deletion, and nanotechnology studies support the notion for its development as a novel targeted or adjuvant therapy in the treatment of respiratory diseases.</p></sec><sec id="S6"><title>Author Contributions</title><p>AW and TT wrote and edited the manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by the Ministry of Education Academic Research Fund under the Tier 2 (No. MOE2015-T2-2-072) and the NUHS Bench-to-Bedside grant (NUHSRO/2014/078/STB/B2B FY14/05) to TT.</p></fn></fn-group><ack><p><xref ref-type="fig" rid="F1">Figure 1</xref> was created with BioRender.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>J.</given-names></name><name><surname>Lijovic</surname><given-names>M.</given-names></name><name><surname>Ashman</surname><given-names>L. K.</given-names></name><name><surname>Kan</surname><given-names>K.</given-names></name><name><surname>Frauman</surname><given-names>A. G.</given-names></name></person-group> (<year>2004</year>). <article-title>CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?</article-title>
<source><italic>Cancer Epidemiol. Biomarkers Prev.</italic></source>
<volume>13</volume>
<fpage>1717</fpage>&#x02013;<lpage>1721</lpage>. <?supplied-pmid 15533898?><pub-id pub-id-type="pmid">15533898</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashman</surname><given-names>L. K.</given-names></name></person-group> (<year>2002</year>). <article-title>CD151.</article-title>
<source><italic>J. Biol. Regul. Homeost. Agents</italic></source>
<volume>16</volume>
<fpage>223</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">12456024</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashman</surname><given-names>L. K.</given-names></name><name><surname>Aylett</surname><given-names>G. W.</given-names></name><name><surname>Mehrabani</surname><given-names>P. A.</given-names></name><name><surname>Bendall</surname><given-names>L. J.</given-names></name><name><surname>Niutta</surname><given-names>S.</given-names></name><name><surname>Cambareri</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>1991</year>). <article-title>The murine monoclonal antibody, 14A2.<italic>H1</italic>, identifies a novel platelet surface antigen.</article-title>
<source><italic>Br. J. Haematol.</italic></source>
<volume>79</volume>
<fpage>263</fpage>&#x02013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.1991.tb04531.x</pub-id>
<?supplied-pmid 1958484?><pub-id pub-id-type="pmid">1958484</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>G.</given-names></name><name><surname>Novitskaya</surname><given-names>V.</given-names></name><name><surname>Sadej</surname><given-names>R.</given-names></name><name><surname>Pochec</surname><given-names>E.</given-names></name><name><surname>Litynska</surname><given-names>A.</given-names></name><name><surname>Hartmann</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Tetraspanin CD151 regulates glycosylation of (alpha)3(beta)1 integrin.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>283</volume>
<fpage>35445</fpage>&#x02013;<lpage>35454</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M806394200</pub-id>
<?supplied-pmid 18852263?><pub-id pub-id-type="pmid">18852263</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>P. J.</given-names></name></person-group> (<year>1996</year>). <article-title>Pathophysiology of asthma.</article-title>
<source><italic>Br. J. Clin. Pharmacol.</italic></source>
<volume>42</volume>
<fpage>3</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">8807137</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>E. D.</given-names></name><name><surname>Hurd</surname><given-names>S. S.</given-names></name><name><surname>Barnes</surname><given-names>P. J.</given-names></name><name><surname>Bousquet</surname><given-names>J.</given-names></name><name><surname>Drazen</surname><given-names>J. M.</given-names></name><name><surname>Fitzgerald</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Global strategy for asthma management and prevention: GINA executive summary.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>31</volume>
<fpage>143</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00138707</pub-id>
<?supplied-pmid 18166595?><pub-id pub-id-type="pmid">18166595</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berditchevski</surname><given-names>F.</given-names></name><name><surname>Odintsova</surname><given-names>E.</given-names></name><name><surname>Sawada</surname><given-names>S.</given-names></name><name><surname>Gilbert</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>277</volume>
<fpage>36991</fpage>&#x02013;<lpage>37000</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m205265200</pub-id>
<?supplied-pmid 12110679?><pub-id pub-id-type="pmid">12110679</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>E.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery.</article-title>
<source><italic>Nat. Biotechnol.</italic></source>
<volume>33</volume>
<fpage>941</fpage>&#x02013;<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3330</pub-id>
<?supplied-pmid 26348965?><pub-id pub-id-type="pmid">26348965</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blume</surname><given-names>G.</given-names></name><name><surname>Cevc</surname><given-names>G.</given-names></name><name><surname>Crommelin</surname><given-names>M. D.</given-names></name><name><surname>Bakker-Woudenberg</surname><given-names>I. A.</given-names></name><name><surname>Kluft</surname><given-names>C.</given-names></name><name><surname>Storm</surname><given-names>G.</given-names></name></person-group> (<year>1993</year>). <article-title>Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times.</article-title>
<source><italic>Biochim. Biophys. Acta</italic></source>
<volume>1149</volume>
<fpage>180</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1016/0005-2736(93)90039-3</pub-id>
<?supplied-pmid 8318529?><pub-id pub-id-type="pmid">8318529</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>C. W.</given-names></name><name><surname>Lin</surname><given-names>S. C.</given-names></name><name><surname>Lai</surname><given-names>Y. Y.</given-names></name><name><surname>Lin</surname><given-names>B. W.</given-names></name><name><surname>Lee</surname><given-names>J. C.</given-names></name><name><surname>Tsai</surname><given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer.</article-title>
<source><italic>Clin. Cancer Res.</italic></source>
<volume>14</volume>
<fpage>8043</fpage>&#x02013;<lpage>8051</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1651</pub-id>
<?supplied-pmid 19073968?><pub-id pub-id-type="pmid">19073968</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Copeland</surname><given-names>B. T.</given-names></name><name><surname>Bowman</surname><given-names>M. J.</given-names></name><name><surname>Ashman</surname><given-names>L. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model.</article-title>
<source><italic>Mol. Cancer Res.</italic></source>
<volume>11</volume>
<fpage>95</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-12-0468</pub-id>
<?supplied-pmid 23131993?><pub-id pub-id-type="pmid">23131993</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryer</surname><given-names>A. M.</given-names></name><name><surname>Thorley</surname><given-names>A. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Nanotechnology in the diagnosis and treatment of lung cancer.</article-title>
<source><italic>Pharmacol. Ther.</italic></source>
<volume>198</volume>
<fpage>189</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.02.010</pub-id>
<?supplied-pmid 30796927?><pub-id pub-id-type="pmid">30796927</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Hoff</surname><given-names>J.</given-names></name><name><surname>Novak</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.</article-title>
<source><italic>Neoplasia</italic></source>
<volume>14</volume>
<fpage>678</fpage>&#x02013;<lpage>689</lpage>. <?supplied-pmid 22952421?><pub-id pub-id-type="pmid">22952421</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>M.</given-names></name><name><surname>Nakagawa</surname><given-names>S.</given-names></name><name><surname>Higashi</surname><given-names>T.</given-names></name><name><surname>Vincek</surname><given-names>A.</given-names></name><name><surname>Venkatesh</surname><given-names>A.</given-names></name><name><surname>Ruiz De Galarreta</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.</article-title>
<source><italic>Nanomedicine</italic></source>
<volume>14</volume>
<fpage>317</fpage>&#x02013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2017.11.004</pub-id>
<?supplied-pmid 29157977?><pub-id pub-id-type="pmid">29157977</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferkol</surname><given-names>T.</given-names></name><name><surname>Schraufnagel</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>The global burden of respiratory disease.</article-title>
<source><italic>Ann. Am. Thorac. Soc.</italic></source>
<volume>11</volume>
<fpage>404</fpage>&#x02013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201311-405PS</pub-id>
<?supplied-pmid 24673696?><pub-id pub-id-type="pmid">24673696</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>O. M.</given-names></name><name><surname>Levert-Mignon</surname><given-names>A. J.</given-names></name><name><surname>Lehane</surname><given-names>C. W.</given-names></name><name><surname>Botelho</surname><given-names>N. K.</given-names></name><name><surname>Maag</surname><given-names>J. L.</given-names></name><name><surname>Thomas</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CD151 gene and protein expression provides independent prognostic information for patients with adenocarcinoma of the esophagus and gastroesophageal junction treated by esophagectomy.</article-title>
<source><italic>Ann. Surg. Oncol.</italic></source>
<volume>23</volume>
<fpage>746</fpage>&#x02013;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-016-5504-9</pub-id>
<?supplied-pmid 27577713?><pub-id pub-id-type="pmid">27577713</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitter</surname><given-names>S.</given-names></name><name><surname>Tetaz</surname><given-names>T. J.</given-names></name><name><surname>Berndt</surname><given-names>M. C.</given-names></name><name><surname>Ashman</surname><given-names>L. K.</given-names></name></person-group> (<year>1995</year>). <article-title>Molecular cloning of cDNA encoding a novel platelet-endothelial cell tetra-span antigen, PETA-3.</article-title>
<source><italic>Blood</italic></source>
<volume>86</volume>
<fpage>1348</fpage>&#x02013;<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v86.4.1348.bloodjournal8641348</pub-id>
<?supplied-pmid 7632941?><pub-id pub-id-type="pmid">7632941</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>M.</given-names></name><name><surname>Muratori</surname><given-names>C.</given-names></name><name><surname>Corso</surname><given-names>S.</given-names></name><name><surname>Tenaglia</surname><given-names>E.</given-names></name><name><surname>Bertotti</surname><given-names>A.</given-names></name><name><surname>Capparuccia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>285</volume>
<fpage>38756</fpage>&#x02013;<lpage>38764</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.145417</pub-id>
<?supplied-pmid 20937830?><pub-id pub-id-type="pmid">20937830</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujishima</surname><given-names>S.</given-names></name><name><surname>Shiomi</surname><given-names>T.</given-names></name><name><surname>Yamashita</surname><given-names>S.</given-names></name><name><surname>Yogo</surname><given-names>Y.</given-names></name><name><surname>Nakano</surname><given-names>Y.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis.</article-title>
<source><italic>Arch. Pathol. Lab. Med.</italic></source>
<volume>134</volume>
<fpage>1136</fpage>&#x02013;<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1043/2009-0144-OA.1</pub-id>
<?supplied-pmid 20670133?><pub-id pub-id-type="pmid">20670133</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geary</surname><given-names>S. M.</given-names></name><name><surname>Cowin</surname><given-names>A. J.</given-names></name><name><surname>Copeland</surname><given-names>B.</given-names></name><name><surname>Baleato</surname><given-names>R. M.</given-names></name><name><surname>Miyazaki</surname><given-names>K.</given-names></name><name><surname>Ashman</surname><given-names>L. K.</given-names></name></person-group> (<year>2008</year>). <article-title>The role of the tetraspanin CD151 in primary keratinocyte and fibroblast functions: implications for wound healing.</article-title>
<source><italic>Exp. Cell Res.</italic></source>
<volume>314</volume>
<fpage>2165</fpage>&#x02013;<lpage>2175</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2008.04.011</pub-id>
<?supplied-pmid 18534576?><pub-id pub-id-type="pmid">18534576</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>G. J.</given-names></name><name><surname>Loddenkemper</surname><given-names>R.</given-names></name><name><surname>Lundback</surname><given-names>B.</given-names></name><name><surname>Sibille</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Respiratory health and disease in Europe: the new European lung white book.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>42</volume>
<fpage>559</fpage>&#x02013;<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00105513</pub-id>
<?supplied-pmid 24000245?><pub-id pub-id-type="pmid">24000245</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>S. Y.</given-names></name><name><surname>Do</surname><given-names>I. G.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>S. H.</given-names></name><name><surname>Park</surname><given-names>J. O.</given-names></name><name><surname>Kang</surname><given-names>W. K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.</article-title>
<source><italic>Ann. Surg. Oncol.</italic></source>
<volume>21</volume>
<fpage>1099</fpage>&#x02013;<lpage>1106</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-013-3339-1</pub-id>
<?supplied-pmid 24306658?><pub-id pub-id-type="pmid">24306658</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemler</surname><given-names>M. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain.</article-title>
<source><italic>Annu. Rev. Cell Dev. Biol.</italic></source>
<volume>19</volume>
<fpage>397</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.19.111301.153609</pub-id>
<?supplied-pmid 14570575?><pub-id pub-id-type="pmid">14570575</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>R. S.</given-names></name><name><surname>Heymach</surname><given-names>J. V.</given-names></name><name><surname>Lippman</surname><given-names>S. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Lung cancer.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>359</volume>
<fpage>1367</fpage>&#x02013;<lpage>1380</lpage>.<pub-id pub-id-type="pmid">18815398</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>R. S.</given-names></name><name><surname>Morgensztern</surname><given-names>D.</given-names></name><name><surname>Boshoff</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>The biology and management of non-small cell lung cancer.</article-title>
<source><italic>Nature</italic></source>
<volume>553</volume>
<fpage>446</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature25183</pub-id>
<?supplied-pmid 29364287?><pub-id pub-id-type="pmid">29364287</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>F. R.</given-names></name><name><surname>Scagliotti</surname><given-names>G. V.</given-names></name><name><surname>Mulshine</surname><given-names>J. L.</given-names></name><name><surname>Kwon</surname><given-names>R.</given-names></name><name><surname>Curran</surname><given-names>W. J.</given-names><suffix>Jr.</suffix></name><name><surname>Wu</surname><given-names>Y. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Lung cancer: current therapies and new targeted treatments.</article-title>
<source><italic>Lancet</italic></source>
<volume>389</volume>
<fpage>299</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)30958-8</pub-id>
<?supplied-pmid 27574741?><pub-id pub-id-type="pmid">27574741</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochdorfer</surname><given-names>D.</given-names></name><name><surname>Florin</surname><given-names>L.</given-names></name><name><surname>Sinzger</surname><given-names>C.</given-names></name><name><surname>Lieber</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Tetraspanin CD151 promotes initial events in human cytomegalovirus infection.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>90</volume>
<fpage>6430</fpage>&#x02013;<lpage>6442</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00145-16</pub-id>
<?supplied-pmid 27147745?><pub-id pub-id-type="pmid">27147745</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>L. V.</given-names></name><name><surname>Green</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Warsh</surname><given-names>J. J.</given-names></name><name><surname>Li</surname><given-names>P. P.</given-names></name></person-group> (<year>2001</year>). <article-title>Tetraspan protein CD151: a common target of mood stabilizing drugs?</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>25</volume>
<fpage>729</fpage>&#x02013;<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1016/s0893-133x(01)00269-x</pub-id>
<?supplied-pmid 11682256?><pub-id pub-id-type="pmid">11682256</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Takimoto</surname><given-names>T.</given-names></name><name><surname>Hemler</surname><given-names>M. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Integrin-independent support of cancer drug resistance by tetraspanin CD151.</article-title>
<source><italic>Cell. Mol. Life Sci.</italic></source>
<volume>76</volume>
<fpage>1595</fpage>&#x02013;<lpage>1604</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-019-03014-7</pub-id>
<?supplied-pmid 30778617?><pub-id pub-id-type="pmid">30778617</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>K. R.</given-names></name><name><surname>Paulsen</surname><given-names>B. S.</given-names></name><name><surname>Baek</surname><given-names>R.</given-names></name><name><surname>Varming</surname><given-names>K.</given-names></name><name><surname>Sorensen</surname><given-names>B. S.</given-names></name><name><surname>Jorgensen</surname><given-names>M. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.</article-title>
<source><italic>J. Extracell. Vesicles</italic></source>
<volume>4</volume>:<issue>26659</issue>. <pub-id pub-id-type="doi">10.3402/jev.v4.26659</pub-id>
<?supplied-pmid 25735706?><pub-id pub-id-type="pmid">25735706</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>B. W.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Chung</surname><given-names>H. Y.</given-names></name><name><surname>Han</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. B.</given-names></name></person-group> (<year>2013</year>). <article-title>Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.</article-title>
<source><italic>J. Cancer Res. Clin. Oncol.</italic></source>
<volume>139</volume>
<fpage>1835</fpage>&#x02013;<lpage>1843</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-013-1503-4</pub-id>
<?supplied-pmid 24005419?><pub-id pub-id-type="pmid">24005419</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamatic Crew</surname><given-names>V.</given-names></name><name><surname>Burton</surname><given-names>N.</given-names></name><name><surname>Kagan</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>C. A.</given-names></name><name><surname>Levene</surname><given-names>C.</given-names></name><name><surname>Flinter</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin.</article-title>
<source><italic>Blood</italic></source>
<volume>104</volume>
<fpage>2217</fpage>&#x02013;<lpage>2223</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-04-1512</pub-id>
<?supplied-pmid 15265795?><pub-id pub-id-type="pmid">15265795</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamatic Crew</surname><given-names>V.</given-names></name><name><surname>Poole</surname><given-names>J.</given-names></name><name><surname>Long</surname><given-names>S.</given-names></name><name><surname>Warke</surname><given-names>N.</given-names></name><name><surname>Colavecchia</surname><given-names>C.</given-names></name><name><surname>Burton</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Two MER2-negative individuals with the same novel CD151 mutation and evidence for clinical significance of anti-MER2.</article-title>
<source><italic>Transfusion</italic></source>
<volume>48</volume>
<fpage>1912</fpage>&#x02013;<lpage>1916</lpage>. <pub-id pub-id-type="doi">10.1111/j.1537-2995.2008.01792.x</pub-id>
<?supplied-pmid 18522704?><pub-id pub-id-type="pmid">18522704</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>A. W.</given-names></name><name><surname>Shi</surname><given-names>G. M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X. Y.</given-names></name><name><surname>Shi</surname><given-names>Y. H.</given-names></name><name><surname>Ding</surname><given-names>Z. B.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>CD151 amplifies signaling by integrin &#x003b1;6&#x003b2;1 to PI3K and induces the epithelial&#x02013;mesenchymal transition in HCC cells.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>140</volume>
<fpage>1629.e15</fpage>&#x02013;<lpage>1641.e15</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2011.02.008</pub-id>
<?supplied-pmid 21320503?><pub-id pub-id-type="pmid">21320503</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>A. W.</given-names></name><name><surname>Shi</surname><given-names>G. M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>F. Z.</given-names></name><name><surname>Ding</surname><given-names>Z. B.</given-names></name><name><surname>Hu</surname><given-names>M. Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>49</volume>
<fpage>491</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1002/hep.22639</pub-id>
<?supplied-pmid 19065669?><pub-id pub-id-type="pmid">19065669</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>Q.</given-names></name><name><surname>Costa</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Hypoxia-inducible factor-1 (HIF-1).</article-title>
<source><italic>Mol. Pharmacol.</italic></source>
<volume>70</volume>
<fpage>1469</fpage>&#x02013;<lpage>1480</lpage>. <?supplied-pmid 16887934?><pub-id pub-id-type="pmid">16887934</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>T. E.</given-names><suffix>Jr.</suffix></name><name><surname>Pardo</surname><given-names>A.</given-names></name><name><surname>Selman</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Idiopathic pulmonary fibrosis.</article-title>
<source><italic>Lancet</italic></source>
<volume>378</volume>
<fpage>1949</fpage>&#x02013;<lpage>1961</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60052-4</pub-id>
<?supplied-pmid 21719092?><pub-id pub-id-type="pmid">21719092</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klibanov</surname><given-names>A. L.</given-names></name><name><surname>Maruyama</surname><given-names>K.</given-names></name><name><surname>Torchilin</surname><given-names>V. P.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group> (<year>1990</year>). <article-title>Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.</article-title>
<source><italic>FEBS Lett.</italic></source>
<volume>268</volume>
<fpage>235</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(90)81016-h</pub-id>
<?supplied-pmid 2384160?><pub-id pub-id-type="pmid">2384160</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klosek</surname><given-names>S. K.</given-names></name><name><surname>Nakashiro</surname><given-names>K.</given-names></name><name><surname>Hara</surname><given-names>S.</given-names></name><name><surname>Shintani</surname><given-names>S.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Hamakawa</surname><given-names>H.</given-names></name></person-group> (<year>2005</year>). <article-title>CD151 forms a functional complex with c-Met in human salivary gland cancer cells.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>336</volume>
<fpage>408</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2005.08.106</pub-id>
<?supplied-pmid 16139245?><pub-id pub-id-type="pmid">16139245</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>M.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Miyake</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Fujita</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.</article-title>
<source><italic>Int. J. Cancer</italic></source>
<volume>97</volume>
<fpage>336</fpage>&#x02013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.1605</pub-id>
<?supplied-pmid 11774285?><pub-id pub-id-type="pmid">11774285</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreidberg</surname><given-names>J. A.</given-names></name><name><surname>Donovan</surname><given-names>M. J.</given-names></name><name><surname>Goldstein</surname><given-names>S. L.</given-names></name><name><surname>Rennke</surname><given-names>H.</given-names></name><name><surname>Shepherd</surname><given-names>K.</given-names></name><name><surname>Jones</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis.</article-title>
<source><italic>Development</italic></source>
<volume>122</volume>
<fpage>3537</fpage>&#x02013;<lpage>3547</lpage>. <?supplied-pmid 8951069?><pub-id pub-id-type="pmid">8951069</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Ishigatsubo</surname><given-names>Y.</given-names></name><name><surname>Aoki</surname><given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>Pathology of asthma.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>4</volume>:<issue>263</issue>
<pub-id pub-id-type="doi">10.3389/fmicb.2013.00263</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>M. J.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>J. Y.</given-names></name><name><surname>Oh</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Park</surname><given-names>Y. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.</article-title>
<source><italic>Br. J. Cancer</italic></source>
<volume>106</volume>
<fpage>923</fpage>&#x02013;<lpage>930</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2012.11</pub-id>
<?supplied-pmid 22294188?><pub-id pub-id-type="pmid">22294188</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>M. J.</given-names></name><name><surname>Seo</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Choi</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>T. E.</given-names></name><name><surname>Lee</surname><given-names>D. H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prognostic significance of CD151 overexpression in non-small cell lung cancer.</article-title>
<source><italic>Lung Cancer</italic></source>
<volume>81</volume>
<fpage>109</fpage>&#x02013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2013.03.014</pub-id>
<?supplied-pmid 23570797?><pub-id pub-id-type="pmid">23570797</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Suh</surname><given-names>Y. L.</given-names></name><name><surname>Park</surname><given-names>T. I.</given-names></name><name><surname>Do</surname><given-names>I. G.</given-names></name><name><surname>Seol</surname><given-names>H. J.</given-names></name><name><surname>Nam</surname><given-names>D. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.</article-title>
<source><italic>J. Surg. Oncol.</italic></source>
<volume>107</volume>
<fpage>646</fpage>&#x02013;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1002/jso.23249</pub-id>
<?supplied-pmid 22926763?><pub-id pub-id-type="pmid">22926763</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>D.</given-names></name><name><surname>Zuo</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Effects of tetraspanin CD151 inhibition on A549 human lung adenocarcinoma cells.</article-title>
<source><italic>Mol. Med. Rep.</italic></source>
<volume>11</volume>
<fpage>1258</fpage>&#x02013;<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2014.2774</pub-id>
<?supplied-pmid 25351816?><pub-id pub-id-type="pmid">25351816</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>X. H.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H. X.</given-names></name><name><surname>Knoblich</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Tetraspanin CD151 plays a key role in skin squamous cell carcinoma.</article-title>
<source><italic>Oncogene</italic></source>
<volume>32</volume>
<fpage>1772</fpage>&#x02013;<lpage>1783</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.205</pub-id>
<?supplied-pmid 22824799?><pub-id pub-id-type="pmid">22824799</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>W. M.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Cox</surname><given-names>J. V.</given-names></name><name><surname>Zhang</surname><given-names>X. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Tetraspanin CD151 promotes cell migration by regulating integrin trafficking.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>282</volume>
<fpage>31631</fpage>&#x02013;<lpage>31642</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m701165200</pub-id>
<?supplied-pmid 17716972?><pub-id pub-id-type="pmid">17716972</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>F. J.</given-names></name><name><surname>Collard</surname><given-names>H. R.</given-names></name><name><surname>Pardo</surname><given-names>A.</given-names></name><name><surname>Raghu</surname><given-names>G.</given-names></name><name><surname>Richeldi</surname><given-names>L.</given-names></name><name><surname>Selman</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Idiopathic pulmonary fibrosis.</article-title>
<source><italic>Nat. Rev. Dis. Primers</italic></source>
<volume>3</volume>:<issue>17074</issue>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.74</pub-id>
<?supplied-pmid 29052582?><pub-id pub-id-type="pmid">29052582</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name></person-group> (<year>1986</year>). <article-title>A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>46</volume>
<fpage>6387</fpage>&#x02013;<lpage>6392</lpage>. <?supplied-pmid 2946403?><pub-id pub-id-type="pmid">2946403</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzocca</surname><given-names>A.</given-names></name><name><surname>Carloni</surname><given-names>V.</given-names></name><name><surname>Sciammetta</surname><given-names>S.</given-names></name><name><surname>Cordella</surname><given-names>C.</given-names></name><name><surname>Pantaleo</surname><given-names>P.</given-names></name><name><surname>Caldini</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>37</volume>
<fpage>322</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1016/s0168-8278(02)00175-7</pub-id>
<?supplied-pmid 12175627?><pub-id pub-id-type="pmid">12175627</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medrano</surname><given-names>M.</given-names></name><name><surname>Communal</surname><given-names>L.</given-names></name><name><surname>Brown</surname><given-names>K. R.</given-names></name><name><surname>Iwanicki</surname><given-names>M.</given-names></name><name><surname>Normand</surname><given-names>J.</given-names></name><name><surname>Paterson</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Interrogation of functional cell-surface markers identifies cd151 dependency in high-grade serous ovarian cancer.</article-title>
<source><italic>Cell Rep.</italic></source>
<volume>18</volume>
<fpage>2343</fpage>&#x02013;<lpage>2358</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.028</pub-id>
<?supplied-pmid 28273451?><pub-id pub-id-type="pmid">28273451</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname><given-names>A. M.</given-names></name><name><surname>Hoogduijn</surname><given-names>M. J.</given-names></name><name><surname>Borras</surname><given-names>F. E.</given-names></name><name><surname>Franquesa</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Therapeutic potential of extracellular vesicles.</article-title>
<source><italic>Front. Immunol.</italic></source>
<volume>5</volume>:<issue>658</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00658</pub-id>
<?supplied-pmid 25566267?><pub-id pub-id-type="pmid">25566267</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>A. L.</given-names></name><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Pardo</surname><given-names>A.</given-names></name><name><surname>Selman</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.</article-title>
<source><italic>Nat. Rev. Drug Discov.</italic></source>
<volume>16</volume>
<fpage>755</fpage>&#x02013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2017.170</pub-id>
<?supplied-pmid 28983101?><pub-id pub-id-type="pmid">28983101</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>A.</given-names></name><name><surname>Paul</surname><given-names>M.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Recent progress in the theranostics application of nanomedicine in lung cancer.</article-title>
<source><italic>Cancers</italic></source>
<volume>11</volume>:<issue>597</issue>. <pub-id pub-id-type="doi">10.3390/cancers11050597</pub-id>
<?supplied-pmid 31035440?><pub-id pub-id-type="pmid">31035440</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>N. M.</given-names></name><name><surname>Miner</surname><given-names>J. H.</given-names></name><name><surname>Pierce</surname><given-names>R. A.</given-names></name><name><surname>Senior</surname><given-names>R. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Laminin alpha 5 is required for lobar septation and visceral pleural basement membrane formation in the developing mouse lung.</article-title>
<source><italic>Dev. Biol.</italic></source>
<volume>246</volume>
<fpage>231</fpage>&#x02013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1006/dbio.2002.0658</pub-id>
<?supplied-pmid 12051813?><pub-id pub-id-type="pmid">12051813</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>K. G.</given-names></name><name><surname>Wood</surname><given-names>J. M.</given-names></name><name><surname>Zambon</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Influenza.</article-title>
<source><italic>Lancet</italic></source>
<volume>362</volume>
<fpage>1733</fpage>&#x02013;<lpage>1745</lpage>. <?supplied-pmid 14643124?><pub-id pub-id-type="pmid">14643124</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poelstra</surname><given-names>K.</given-names></name><name><surname>Beljaars</surname><given-names>L.</given-names></name><name><surname>Melgert</surname><given-names>B. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver.</article-title>
<source><italic>Drug Discov. Today</italic></source>
<volume>18</volume>
<fpage>1237</fpage>&#x02013;<lpage>1242</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2013.05.013</pub-id>
<?supplied-pmid 23732178?><pub-id pub-id-type="pmid">23732178</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Tam</surname><given-names>J. K. C.</given-names></name><name><surname>Tan</surname><given-names>S. S. L.</given-names></name><name><surname>Tai</surname><given-names>Y. K.</given-names></name><name><surname>Chin</surname><given-names>C. Y.</given-names></name><name><surname>Stewart</surname><given-names>A. G.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>CD151, a laminin receptor showing increased expression in asthmatic patients, contributes to airway hyperresponsiveness through calcium signaling.</article-title>
<source><italic>J. Allergy Clin. Immunol.</italic></source>
<volume>139</volume>
<fpage>82.e5</fpage>&#x02013;<lpage>92.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2016.03.029</pub-id>
<?supplied-pmid 27233153?><pub-id pub-id-type="pmid">27233153</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>K. S.</given-names></name><name><surname>Tan</surname><given-names>S. S. L.</given-names></name><name><surname>Seet</surname><given-names>J. E.</given-names></name><name><surname>Arumugam</surname><given-names>T. V.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>CD151, a novel host factor of nuclear export signaling in influenza virus infection.</article-title>
<source><italic>J. Allergy Clin. Immunol.</italic></source>
<volume>141</volume>
<fpage>1799</fpage>&#x02013;<lpage>1817</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2017.11.032</pub-id>
<?supplied-pmid 29274410?><pub-id pub-id-type="pmid">29274410</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reck</surname><given-names>M.</given-names></name><name><surname>Heigener</surname><given-names>D. F.</given-names></name><name><surname>Mok</surname><given-names>T.</given-names></name><name><surname>Soria</surname><given-names>J. C.</given-names></name><name><surname>Rabe</surname><given-names>K. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Management of non-small-cell lung cancer: recent developments.</article-title>
<source><italic>Lancet</italic></source>
<volume>382</volume>
<fpage>709</fpage>&#x02013;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61502-0</pub-id>
<?supplied-pmid 23972814?><pub-id pub-id-type="pmid">23972814</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddel</surname><given-names>H. K.</given-names></name><name><surname>Bateman</surname><given-names>E. D.</given-names></name><name><surname>Becker</surname><given-names>A.</given-names></name><name><surname>Boulet</surname><given-names>L. P.</given-names></name><name><surname>Cruz</surname><given-names>A. A.</given-names></name><name><surname>Drazen</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A summary of the new GINA strategy: a roadmap to asthma control.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>46</volume>
<fpage>622</fpage>&#x02013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1183/13993003.00853-2015</pub-id>
<?supplied-pmid 26206872?><pub-id pub-id-type="pmid">26206872</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname><given-names>L.</given-names></name><name><surname>Collard</surname><given-names>H. R.</given-names></name><name><surname>Jones</surname><given-names>M. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Idiopathic pulmonary fibrosis.</article-title>
<source><italic>Lancet</italic></source>
<volume>389</volume>
<fpage>1941</fpage>&#x02013;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)30866-8</pub-id>
<?supplied-pmid 28365056?><pub-id pub-id-type="pmid">28365056</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romanska</surname><given-names>H. M.</given-names></name><name><surname>Potemski</surname><given-names>P.</given-names></name><name><surname>Collins</surname><given-names>S. I.</given-names></name><name><surname>Williams</surname><given-names>H.</given-names></name><name><surname>Parmar</surname><given-names>S.</given-names></name><name><surname>Berditchevski</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Loss of CD151/Tspan24 from the complex with integrin alpha3beta1 in invasive front of the tumour is a negative predictor of disease-free survival in oral squamous cell carcinoma.</article-title>
<source><italic>Oral Oncol.</italic></source>
<volume>49</volume>
<fpage>224</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.oraloncology.2012.09.013</pub-id>
<?supplied-pmid 23099281?><pub-id pub-id-type="pmid">23099281</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romanska</surname><given-names>H. M.</given-names></name><name><surname>Potemski</surname><given-names>P.</given-names></name><name><surname>Krakowska</surname><given-names>M.</given-names></name><name><surname>Mieszkowska</surname><given-names>M.</given-names></name><name><surname>Chaudhri</surname><given-names>S.</given-names></name><name><surname>Kordek</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Lack of CD151/integrin alpha3beta1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.</article-title>
<source><italic>Br. J. Cancer</italic></source>
<volume>113</volume>
<fpage>1350</fpage>&#x02013;<lpage>1357</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2015.344</pub-id>
<?supplied-pmid 26418423?><pub-id pub-id-type="pmid">26418423</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblum</surname><given-names>D.</given-names></name><name><surname>Joshi</surname><given-names>N.</given-names></name><name><surname>Tao</surname><given-names>W.</given-names></name><name><surname>Karp</surname><given-names>J. M.</given-names></name><name><surname>Peer</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Progress and challenges towards targeted delivery of cancer therapeutics.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>9</volume>:<issue>1410</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-03705-y</pub-id>
<?supplied-pmid 29650952?><pub-id pub-id-type="pmid">29650952</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>N.</given-names></name><name><surname>Kreft</surname><given-names>M.</given-names></name><name><surname>Van Den Bergh Weerman</surname><given-names>M. A.</given-names></name><name><surname>Beynon</surname><given-names>A. J.</given-names></name><name><surname>Peters</surname><given-names>T. A.</given-names></name><name><surname>Weening</surname><given-names>J. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Kidney failure in mice lacking the tetraspanin CD151.</article-title>
<source><italic>J. Cell Biol.</italic></source>
<volume>175</volume>
<fpage>33</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200603073</pub-id>
<?supplied-pmid 17015618?><pub-id pub-id-type="pmid">17015618</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadej</surname><given-names>R.</given-names></name><name><surname>Romanska</surname><given-names>H.</given-names></name><name><surname>Kavanagh</surname><given-names>D.</given-names></name><name><surname>Baldwin</surname><given-names>G.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Kalia</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>70</volume>
<fpage>6059</fpage>&#x02013;<lpage>6070</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3497</pub-id>
<?supplied-pmid 20570898?><pub-id pub-id-type="pmid">20570898</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandfeld-Paulsen</surname><given-names>B.</given-names></name><name><surname>Jakobsen</surname><given-names>K. R.</given-names></name><name><surname>Baek</surname><given-names>R.</given-names></name><name><surname>Folkersen</surname><given-names>B. H.</given-names></name><name><surname>Rasmussen</surname><given-names>T. R.</given-names></name><name><surname>Meldgaard</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Exosomal proteins as diagnostic biomarkers in lung cancer.</article-title>
<source><italic>J. Thorac. Oncol.</italic></source>
<volume>11</volume>
<fpage>1701</fpage>&#x02013;<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2016.05.034</pub-id>
<?supplied-pmid 27343445?><pub-id pub-id-type="pmid">27343445</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>K. D.</given-names></name><name><surname>Berditchevski</surname><given-names>F.</given-names></name><name><surname>Florin</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>The tetraspanin CD151 in papillomavirus infection.</article-title>
<source><italic>Viruses</italic></source>
<volume>6</volume>
<fpage>893</fpage>&#x02013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.3390/v6020893</pub-id>
<?supplied-pmid 24553111?><pub-id pub-id-type="pmid">24553111</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigeta</surname><given-names>M.</given-names></name><name><surname>Sanzen</surname><given-names>N.</given-names></name><name><surname>Ozawa</surname><given-names>M.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Sekiguchi</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization.</article-title>
<source><italic>J. Cell Biol.</italic></source>
<volume>163</volume>
<fpage>165</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200301075</pub-id>
<?supplied-pmid 14557253?><pub-id pub-id-type="pmid">14557253</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Tenson</surname><given-names>T.</given-names></name><name><surname>Min</surname><given-names>J. Y.</given-names></name><name><surname>Kainov</surname><given-names>D. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Influenza virus infection, interferon response, viral counter-response, and apoptosis.</article-title>
<source><italic>Viruses</italic></source>
<volume>9</volume>:<issue>E223</issue>. <pub-id pub-id-type="doi">10.3390/v9080223</pub-id>
<?supplied-pmid 28805681?><pub-id pub-id-type="pmid">28805681</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiomi</surname><given-names>T.</given-names></name><name><surname>Inoki</surname><given-names>I.</given-names></name><name><surname>Kataoka</surname><given-names>F.</given-names></name><name><surname>Ohtsuka</surname><given-names>T.</given-names></name><name><surname>Hashimoto</surname><given-names>G.</given-names></name><name><surname>Nemori</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151.</article-title>
<source><italic>Lab. Invest.</italic></source>
<volume>85</volume>
<fpage>1489</fpage>&#x02013;<lpage>1506</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.3700351</pub-id>
<?supplied-pmid 16200075?><pub-id pub-id-type="pmid">16200075</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sincock</surname><given-names>P. M.</given-names></name><name><surname>Mayrhofer</surname><given-names>G.</given-names></name><name><surname>Ashman</surname><given-names>L. K.</given-names></name></person-group> (<year>1997</year>). <article-title>Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin.</article-title>
<source><italic>J. Histochem. Cytochem.</italic></source>
<volume>45</volume>
<fpage>515</fpage>&#x02013;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1177/002215549704500404</pub-id>
<?supplied-pmid 9111230?><pub-id pub-id-type="pmid">9111230</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stipp</surname><given-names>C. S.</given-names></name><name><surname>Kolesnikova</surname><given-names>T. V.</given-names></name><name><surname>Hemler</surname><given-names>M. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Functional domains in tetraspanin proteins.</article-title>
<source><italic>Trends Biochem. Sci.</italic></source>
<volume>28</volume>
<fpage>106</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/s0968-0004(02)00014-2</pub-id>
<?supplied-pmid 12575999?><pub-id pub-id-type="pmid">12575999</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Miyazaki</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Sakai</surname><given-names>M.</given-names></name><name><surname>Sano</surname><given-names>A.</given-names></name><name><surname>Inose</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness.</article-title>
<source><italic>Ann. Surg. Oncol.</italic></source>
<volume>18</volume>
<fpage>888</fpage>&#x02013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-010-1387-3</pub-id>
<?supplied-pmid 20978946?><pub-id pub-id-type="pmid">20978946</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>Y.</given-names></name><name><surname>Kazarov</surname><given-names>A. R.</given-names></name><name><surname>Butterfield</surname><given-names>C. E.</given-names></name><name><surname>Hopkins</surname><given-names>B. D.</given-names></name><name><surname>Benjamin</surname><given-names>L. E.</given-names></name><name><surname>Kaipainen</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro.</article-title>
<source><italic>Blood</italic></source>
<volume>109</volume>:<issue>1524</issue>. <pub-id pub-id-type="doi">10.1182/blood-2006-08-041970</pub-id>
<?supplied-pmid 17023588?><pub-id pub-id-type="pmid">17023588</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Kazarov</surname><given-names>A. R.</given-names></name><name><surname>Epardaud</surname><given-names>M.</given-names></name><name><surname>Elpek</surname><given-names>K.</given-names></name><name><surname>Turley</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Diminished metastasis in tetraspanin CD151&#x02013;knockout mice.</article-title>
<source><italic>Blood</italic></source>
<volume>118</volume>:<issue>464</issue>. <pub-id pub-id-type="doi">10.1182/blood-2010-08-302240</pub-id>
<?supplied-pmid 21536858?><pub-id pub-id-type="pmid">21536858</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>J. E.</given-names></name><name><surname>Brooks</surname><given-names>P. C.</given-names></name><name><surname>Lin</surname><given-names>J. M.</given-names></name><name><surname>Quigley</surname><given-names>J. P.</given-names></name></person-group> (<year>1999</year>). <article-title>Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>59</volume>
<fpage>3812</fpage>&#x02013;<lpage>3820</lpage>. <?supplied-pmid 10447000?><pub-id pub-id-type="pmid">10447000</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thali</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Tetraspanin functions during HIV-1 and influenza virus replication.</article-title>
<source><italic>Biochem. Soc. Trans.</italic></source>
<volume>39</volume>
<fpage>529</fpage>&#x02013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1042/BST0390529</pub-id>
<?supplied-pmid 21428933?><pub-id pub-id-type="pmid">21428933</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuhara</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Ishida</surname><given-names>H.</given-names></name><name><surname>Taki</surname><given-names>T.</given-names></name><name><surname>Tachibana</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Clinical significance of CD151 gene expression in non-small cell lung cancer.</article-title>
<source><italic>Clin. Cancer Res.</italic></source>
<volume>7</volume>
<fpage>4109</fpage>&#x02013;<lpage>4114</lpage>. <?supplied-pmid 11751509?><pub-id pub-id-type="pmid">11751509</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujino</surname><given-names>K.</given-names></name><name><surname>Takeda</surname><given-names>Y.</given-names></name><name><surname>Arai</surname><given-names>T.</given-names></name><name><surname>Shintani</surname><given-names>Y.</given-names></name><name><surname>Inagaki</surname><given-names>R.</given-names></name><name><surname>Saiga</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>186</volume>
<fpage>170</fpage>&#x02013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201201-0117OC</pub-id>
<?supplied-pmid 22592804?><pub-id pub-id-type="pmid">22592804</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahidnezhad</surname><given-names>H.</given-names></name><name><surname>Youssefian</surname><given-names>L.</given-names></name><name><surname>Saeidian</surname><given-names>A. H.</given-names></name><name><surname>Mahmoudi</surname><given-names>H.</given-names></name><name><surname>Touati</surname><given-names>A.</given-names></name><name><surname>Abiri</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Recessive mutation in tetraspanin CD151 causes Kindler syndrome-like epidermolysis bullosa with multi-systemic manifestations including nephropathy.</article-title>
<source><italic>Matrix Biol.</italic></source>
<volume>66</volume>
<fpage>22</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.matbio.2017.11.003</pub-id>
<?supplied-pmid 29138120?><pub-id pub-id-type="pmid">29138120</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Spriel</surname><given-names>A. B.</given-names></name><name><surname>Figdor</surname><given-names>C. G.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of tetraspanins in the pathogenesis of infectious diseases.</article-title>
<source><italic>Microbes Infect.</italic></source>
<volume>12</volume>
<fpage>106</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2009.11.001</pub-id>
<?supplied-pmid 19896556?><pub-id pub-id-type="pmid">19896556</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>M. D.</given-names></name><name><surname>Geary</surname><given-names>S. M.</given-names></name><name><surname>Fitter</surname><given-names>S.</given-names></name><name><surname>Moseley</surname><given-names>G. W.</given-names></name><name><surname>Lau</surname><given-names>L. M.</given-names></name><name><surname>Sheng</surname><given-names>K. C.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Characterization of mice lacking the tetraspanin superfamily member CD151.</article-title>
<source><italic>Mol. Cell Biol.</italic></source>
<volume>24</volume>
<fpage>5978</fpage>&#x02013;<lpage>5988</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.24.13.5978-5988.2004</pub-id>
<?supplied-pmid 15199151?><pub-id pub-id-type="pmid">15199151</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Sumida</surname><given-names>Y.</given-names></name><name><surname>Fujibayashi</surname><given-names>A.</given-names></name><name><surname>Fukaguchi</surname><given-names>K.</given-names></name><name><surname>Sanzen</surname><given-names>N.</given-names></name><name><surname>Nishiuchi</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The tetraspanin CD151 regulates cell morphology and intracellular signaling on laminin-511.</article-title>
<source><italic>FEBS J.</italic></source>
<volume>275</volume>
<fpage>3335</fpage>&#x02013;<lpage>3351</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06481.x</pub-id>
<?supplied-pmid 18492066?><pub-id pub-id-type="pmid">18492066</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Miller</surname><given-names>J. B.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Kos</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>113</volume>
<fpage>E5702</fpage>&#x02013;<lpage>E5710</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1606886113</pub-id>
<?supplied-pmid 27621434?><pub-id pub-id-type="pmid">27621434</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Claas</surname><given-names>C.</given-names></name><name><surname>Kraeft</surname><given-names>S. K.</given-names></name><name><surname>Chen</surname><given-names>L. B.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Kreidberg</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology.</article-title>
<source><italic>Mol. Biol. Cell</italic></source>
<volume>13</volume>
<fpage>767</fpage>&#x02013;<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.01-05-0275</pub-id>
<?supplied-pmid 11907260?><pub-id pub-id-type="pmid">11907260</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X. H.</given-names></name><name><surname>Flores</surname><given-names>L. M.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Krop</surname><given-names>I. E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>70</volume>
<fpage>2256</fpage>&#x02013;<lpage>2263</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4032</pub-id>
<?supplied-pmid 20197472?><pub-id pub-id-type="pmid">20197472</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X. H.</given-names></name><name><surname>Richardson</surname><given-names>A. L.</given-names></name><name><surname>Torres-Arzayus</surname><given-names>M. I.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Kazarov</surname><given-names>A. R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>CD151 accelerates breast cancer by regulating &#x003b1;(6) integrin function, signaling, and molecular organization.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>68</volume>
<fpage>3204</fpage>&#x02013;<lpage>3213</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2949</pub-id>
<?supplied-pmid 18451146?><pub-id pub-id-type="pmid">18451146</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>S.</given-names></name><name><surname>Mu</surname><given-names>W.</given-names></name><name><surname>Erb</surname><given-names>U.</given-names></name><name><surname>Zoller</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The tetraspanins CD151 and Tspan8 are essential exosome components for the crosstalk between cancer initiating cells and their surrounding.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>6</volume>
<fpage>2366</fpage>&#x02013;<lpage>2384</lpage>. <?supplied-pmid 25544774?><pub-id pub-id-type="pmid">25544774</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zevian</surname><given-names>S.</given-names></name><name><surname>Winterwood</surname><given-names>N. E.</given-names></name><name><surname>Stipp</surname><given-names>C. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by alpha3beta1 versus alpha6beta4 integrin.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>286</volume>
<fpage>7496</fpage>&#x02013;<lpage>7506</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.173583</pub-id>
<?supplied-pmid 21193415?><pub-id pub-id-type="pmid">21193415</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zijlstra</surname><given-names>A.</given-names></name><name><surname>Lewis</surname><given-names>J.</given-names></name><name><surname>Degryse</surname><given-names>B.</given-names></name><name><surname>Stuhlmann</surname><given-names>H.</given-names></name><name><surname>Quigley</surname><given-names>J. P.</given-names></name></person-group> (<year>2008</year>). <article-title>The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.</article-title>
<source><italic>Cancer Cell</italic></source>
<volume>13</volume>
<fpage>221</fpage>&#x02013;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.031</pub-id>
<?supplied-pmid 18328426?><pub-id pub-id-type="pmid">18328426</pub-id></mixed-citation></ref></ref-list></back></article>